Buckeye Health Plan would like to notify you of an upcoming change to their Preferred Drug List.

Effective January 16, 2017, a prior authorization will be required for Tradjenta, Onglyza, and Kombiglyze XR. The preferred products are generic alogliptin, alogliptin/pioglitazone, and alogliptin/metformin.

*Please see attached PDF for more information.

*Please see attached PDF for more information.

Effective January 1, 2017, Medicaid plan sponsors may limit the daily cumulative dose of opioid products a member may obtain at Point of Sale (POS). The daily limit is referred to as the Morphine Equivalent Dose (MED) limit. The cumulative limit is based on a combination of drug strength and a product’s Morphine Milligram Equivalency (MME). The cumulative total daily MED value will be calculated based on the number of opioid drugs prescribed over a period of time which includes incoming claims and active claims history. Depending on the plan, there may be multiple MED limits with varying response levels (Soft or Hard reject).

*Please see attached PDF for more information.

Effective January 1, 2017, CVS Caremark® will begin to administer the prescription benefits for West Virginia Family Health. Please update or create plan member profiles to reflect the changes regarding the following new plan adjudicating through CVS Caremark.

*Please see attached PDF for more information.